MoonLake Immunotherapeutics (MLTX)
$10.41-2.53%Close
SELLCRISIS · day 45
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $860M
- Beta
- 1.08
- P/E (TTM)
- -2.70
- Short % float
- 11.25%
- Days to cover
- 4.2
- SI change
- -10.1%
- 1W
- -4.93%
- 1M
- -17.90%
- vs SPY 1W
- -4.79%
- vs SPY 1M
- -20.41%
Industry peers
FMP comparable companies · ranked by market cap
- ORKASELLOruka Therapeutics, Inc.$5.0BCRISISQ -3$82.11-2.69%
- DNTHSELLDianthus Therapeutics, Inc.$4.6BCRISISQ 2$82.37-4.89%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35-0.14%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$45.95-0.98%
- ALMSSELLAlumis Inc.$884MCRISISQ 0$7.16-7.08%
- ATTOSELLAttovia Therapeutics, Inc.$698MQ -46$16.21+0.89%
- ACRSSELLAclaris Therapeutics, Inc.$535MCRISISQ 9$3.83-3.61%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on MLTX?
- LOPJLB’s latest quantitative signal on MoonLake Immunotherapeutics (MLTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MLTX in?
- MoonLake Immunotherapeutics (MLTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MoonLake Immunotherapeutics (MLTX) do?
- MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials f…